The Only Approved Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm

Stemline Therapeutics, Inc
September 17, 2020

Join Allison Morin, Nurse Practitioner at Northwestern Memorial Hospital, for a virtual webcast at this year’s Oncology Nursing Society (ONS) Bridge. The program will provide an overview on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a clinically aggressive hematologic malignancy that often presents with skin lesions. You’ll also learn about the essential role of nurses in managing patients with BPDCN.

The program aims to increase attendees’ understanding of BPDCN, as well as educate on the efficacy, safety, dosing, and administration of the only approved treatment option for BPDCN.

This program is sponsored by Stemline Therapeutics, Inc.